Extended Data Fig. 7: The anti-ferroptotic effect of UGDH is essential for tumour growth.

a. Representative images of subcutaneous tumours of HeLa UGDH_KO cells expressing a sgRNA resistant UGDH cDNA or an empty vector. b. Tumour weights resulting from implantation of the indicated UGDH_KO cell lines in immunocompromised mice. c. Representative IHC images (20X magnification) of CD45, a pan-immune marker, in tumours resulting from subcutaneous implantation of Karpas299 cells expressing a sgRNA-resistant UGDH cDNA or an empty vector. Scale bars, 100 μm. d. Quantification of CD45 H-scores in tumours described in (c). e. Immunoblot of UGDH in the indicated isogenic cell lines transduced with a doxycycline-inducible shGFP or a shUGDH construct ± doxycycline treatment (doxy, 1 μg/mL) for 24 h. GAPDH included as a loading control. f. Representative images of subcutaneous tumours of Karpas299 cells expressing a doxycycline-inducible shRNA against either GFP (control) or UGDH implanted in mice given sucrose-water with or without doxycycline (doxy, 2 g/L). g. Tumour weights resulting from implantation of Karpas299 cells expressing a doxycycline-inducible shRNA against either GFP (control) or UGDH in immunocompromised mice given sucrose-water with or without doxycycline (doxy, 2 g/L). h. Tumour weights resulting from implantation of the indicated UGDH_KO cell lines expressing a sgRNA-resistant UGDH cDNA treated with daily intraperitoneal injection of vehicle or Lip-1. i. Fold change in tumour weight relative to vehicle-treated empty vector controls for Karpas299 UGDH_KO cells expressing UGDH cDNA or an empty vector in mice treated with vehicle or Lip-1. b, g-i: Boxes represent median, first and third quartiles, and whiskers are range; b, g-i: n = 10 biological replicates. Statistics by two-sided unpaired t-tests compared to empty vector transduced cells (b, d), shGFP-expressing cells (g), or vehicle-treated mice (h, i). For gel source data, see Supplementary Fig. 1.

Source Data